Physiomics Plc provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology in the United Kingdom, the United States, and the European Union Switzerland. The company offers modeling, simulation, and data analysis services covering various ranges of oncology research and development using its proprietary Virtual Tumour predictive software. It also develops technology for use in the field of personalized medicine. The company was incorporated in 2001 and is based in Oxford, the United Kingdom.
Stock data | 2023 | Change |
---|---|---|
Price | $0.008910067716514647 | N/A |
Market Cap | $868.06K | N/A |
Shares Outstanding | 97.42M | 0.05% |
Employees | 10.00 | N/A |
Shareholder Equity | 531.72K | -45.45% |
Valuation | 2023 | Change |
---|---|---|
P/E Ratio | -1.82 | N/A |
P/S Ratio | 1.10 | N/A |
P/B Ratio | 1.63 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | -1.1848 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $788.51K | N/A |
Earnings | -$629.98K | N/A |
EPS | -0.0049 | N/A |
Earnings Yield | -0.5499 | N/A |
Operating Margin | -0.9605 | N/A |
Net income margin | -0.799 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $890.21K | N/A |
Cash on Hand | $549.91K | N/A |
Debt to Equity | 0.3542 | 86.02% |
Current Ratio | $4.63 | -40.65% |